Replimune stock plunges after FDA rejects melanoma treatment application

Replimune (NASDAQ:REPL) shares plunged 77% after the FDA rejected its Biologics License Application for advanced melanoma treatment RP1, citing the IGNYTE trial's inadequacy and lack of substantial effectiveness evidence due to patient population heterogeneity and study design issues, despite no safety concerns. The company expressed surprise, noting prior alignment with the FDA on study design, and plans an urgent Type A meeting to seek a path for accelerated approval, warning that RP1's development may not be viable otherwise.

Analysis

Replimune Group (REPL) experienced a catastrophic 77% decline in its stock price following the receipt of a Complete Response Letter (CRL) from the U.S. FDA, which rejected its Biologics License Application for the advanced melanoma treatment, RP1. The regulatory rejection was based on fundamental deficiencies in the pivotal IGNYTE trial, with the FDA deeming it not "adequate and well-controlled" and lacking substantial evidence of effectiveness. Key criticisms included the heterogeneity of the patient population, which hindered data interpretation, and issues with the confirmatory trial's study design. Notably, the CRL did not raise any safety concerns. Replimune's management expressed surprise, stating these specific issues were not previously flagged during regulatory reviews and that they believed the confirmatory study design was already aligned with the FDA. The company is now pursuing an urgent Type A meeting to find a path forward for accelerated approval, a critical step as management has warned that without it, the development of RP1 "will not be viable," effectively placing the future of its lead asset in severe jeopardy.

Key Decisions for Investors

• Investors should view REPL as a high-risk, event-driven holding, with its near-term value almost entirely dependent on the outcome of the planned Type A meeting with the FDA.
• The stark discrepancy between the company's stated surprise and the FDA's fundamental criticisms of the trial design warrants a critical assessment of management's credibility and a re-evaluation of the company's regulatory strategy.
• Given the CEO's statement on the potential non-viability of the RP1 program and the 77% share price collapse, a reassessment of the stock's fundamental value is necessary, as the asset now carries a significantly higher probability of a complete write-down.